Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

RESOURCES





Resources to Get You Started




FOR PRESCRIBERS


Find the Nearest Apheresis Center With Spectra Optia


Webinars

ADVANCING APHERESIS IN NEUROLOGY: REVIEW OF NEUROLOGICAL DISEASE INDICATIONS FOR PLASMA EXCHANGE

Review the latest evidence-based guidelines at this on-demand webinar.

PLASMA EXCHANGE TREATMENT FOR MYASTHENIA GRAVIS

Hear from Dr. Demeret as she shares her extensive experience in using TPE to treat MG.

THERAPEUTIC PLASMA EXCHANGE IN GBS

Hear from Dr. Alqarni as she shares her experience with TPE for GBS.

PLASMA EXCHANGE: MULTIPLE VENOUS ACCESS VERSUS PERIPHERAL ACCESS?

Hear from professor Dr. Kurt Derfler as he shares his extensive experience with plasma exchange using peripheral access.

IMPLEMENTING PERIPHERAL VENOUS ACCESS USING ULTRASOUND GUIDANCE

Hear from Anna-Marie Eller Thomsen as she shares her experience in implementing an ultrasound-guided peripheral vascular access program and how the program has impacted patients and nurses.

Abstract Summaries

Intensive management and treatment of severe Guillain-Barrè syndrome

Hund EF, Borel CO, Cornblath DR, Hanley DF, McKhann GM. Crit Care Med. 1993;21(3):443-446.


Plasma exchange for Guillain-Barré syndrome (review)

Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2:CD001798.

Safety of plasma exchange therapy in patients with myasthenia gravis

Ebadi H, Barth D, Bril V. Muscle Nerve. 2013;47(4):510-514.

International consensus guidance for management of myasthenia gravis: Executive summary

Sanders DB, Wolfe GI, Benatar M, et al. Neurology. 2016;87(4): 419-425.



Brochures

5 Myths of Plasma Exchange: An Immunomodulatory Therapy


Plasma Exchange for GBS and MG Patients


Guide: How to Order TPE





Case Studies

UCSD Cost Analysis Case Study





Video

How Plasma Exchange Works on Spectra Optia


FOR YOUR PATIENTS















Apheresis-Related Safety Information

Contraindications

Leukocytapheresis is contraindicated in acute myeloid leukemia FAB M3 (acute promyelocytic leukemia) because of the accompanying disseminated intravascular coagulation.1,2 Other contraindications for the use of the Spectra Optia system are limited to those associated with the infusion of solutions and replacement fluids as required by the apheresis procedure and those associated with all types of automated apheresis systems.

Adverse events of apheresis procedures can include

Anxiety, headache, light-headedness, digital and/or facial paresthesia, fever, chills, hematoma, hyperventilation, nausea and vomiting, syncope (fainting), urticaria, hypotension, allergic reactions, infection, hemolysis, thrombosis in patient and device, hypocalcemia, hypokalemia, thrombocytopenia, hypoalbuminemia, anemia, coagulopathy, fatigue, hypomagnesemia, hypogammaglobulinemia, adverse tissue reaction, device failure/disposable set failure, air embolism, blood loss/anemia, electrical shock, fluid imbalance and inadequate separation of blood components.

Reactions to blood products transfused during procedures can include

Hemolytic transfusion reaction, immune-mediated platelet destruction, fever, allergic reactions, anaphylaxis, transfusion-related acute lung injury (TRALI), alloimmunization, posttransfusion purpura (PTP), transfusion-associated graft-versus-host disease (TA-GVHD), circulatory overload, hypothermia, metabolic complications and transmission of infectious diseases and bacteria.3,4

Restricted to prescription use only

  • Operators must be familiar with the system's operating instructions
  • Procedures must be performed by qualified medical personnel.

1Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84(11):3843-3849.

2Daver N, Kantarjian H, Marcucci G, et al. Clinical characteristics and outcomes in patients with acute promyelotic leukaemia and hyperleucocytosis. Br J Haematol. 2015;168(5):646-653.

3AABB. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, MD: AABB; 2017.

4European Directorate for the Quality of Medicines & HealthCare (EDQM). Guide to the Preparation, Use and Quality Assurance of Blood Components. 19th edition. Strasbourg, France: EDQM Council of Europe; 2017.






How Plasma Exchange Works on Spectra Optia

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}